Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial
Randomized Controlled Trial
[키워드] 1:1
95% CI
adverse event
adverse events
alveolar
Analysis
assigned
baseline
block size
cardiovascular disease
center
clinical benefit
Clinical data
clinical trial
complication of COVID-19
concomitant treatment
diabetes
did not reduce
died
dose
double-blind
Effect
Efficacy and safety
eligible
EU Clinical Trial
EudraCT
European
foundation
greater
hazard ratio
heart failure
hospital
hospitalised patient
hypoxaemic respiratory failure
Imatinib
inhibitor
initiative
Invasive mechanical ventilation
IQR
Loading dose
maintain
malignancy
management
mechanical ventilation
median
median age
medication
Medicine
modified intention-to-treat
Mortality
Netherlands
not significantly different
obesity
oedema
outcome
Patient
patients
patients with COVID-19
peripheral oxygen saturation
Placebo
placebo-controlled
platform
Primary outcome
pulmonary disease
randomised
Randomly
receive
receiving
Registered
required
requiring supplemental oxygen
RT-PCR test
SARS-CoV-2
screened
secondary
Sex
stratified
supplemental oxygen
survival
the placebo group
time
Treatment
two group
union
Ventilation
was done
were excluded
with COVID-19
[DOI] 10.1016/S2213-2600(21)00237-X PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1016/S2213-2600(21)00237-X PMC 바로가기 [Article Type] Randomized Controlled Trial